May 2026
📣 VC round data is live. Check it out!
Largest BioTech Public Companies in Netherlands
Benchmark revenue and EBITDA valuation multiples for public comps like
Merus, NewAmsterdam Pharma, Pharvaris, uniQure and Corbion.
 | Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. | -- | -- | $7B | $7B | — | — | ||
| NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases. | $35 | +96% | $4B | $4B | 155.7x | (15.6x) | ||
| Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. | $30 | +79% | $2B | $2B | — | (9.6x) | ||
| uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. | $24 | +67% | $2B | $1B | 62.3x | (8.6x) | ||
| Corbion NV is a Netherlands-based company that produces food ingredients and biobased chemicals. The company distinguishes between the segments Functional Ingredients & Solutions and Health & Nutrition. The Company is a leader in sustainable bio-based ingredients and lactic acid derivatives. The company provides solutions for food preservation, health, and bioplastics through fermentation technology. Its products serve industries including food, pharmaceuticals, personal care, and packaging. Corbion focuses on innovation and sustainability to preserve food, health, and the planet. Geographically, it derives a majority of its revenue from the U.S. | $24 | +8% | $1B | $2B | 1.2x | 7.6x | ||
| Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. | $1 | +22% | $978M | $924M | 2.5x | 26.6x | ||
| Onward Medical NV is developing and commercializing therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company’s technology platforms are based on ONWARD ARC Therapy (ARC Therapy), targeted, programmed electrical stimulation of the spinal cord designed to restore movement, independence, and health in people with SCI. | $3 | -38% | $229M | $166M | 28.3x | (3.8x) | ||
| Median | $24 | +45% | $2B | $2B | 28.3x | (6.2x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.